Akamis Bio, a pioneering clinical-stage oncology company, has successfully secured $60 million in a latest funding round aimed at advancing its innovative T-SIGnÂŽ platform. This substantial investment will significantly bolster Akamisâ mission to transform cancer treatment by harnessing the immune systemâs ability to combat solid tumors. The company is at the forefront of developing a robust portfolio of T-SIGnÂŽ therapeutics, designed specifically to empower patientsâ own immune cells to recognize, attack, and ultimately clear their cancerous cells. Central to their efforts is NG-350A, the lead program currently being investigated in an ongoing Phase 1 clinical study, targeting patients with metastatic or advanced epithelial tumors. This funding is not just a testament to Akamis' cutting-edge approach in oncology but also a critical enabler for the continued expansion of its T-SIGnÂŽ pipeline and furthering its collaborations with esteemed partners in the immuno-oncology space, including Bristol Myers Squibb (BMS), Merck, and the Parker Institute for Cancer Immunotherapy (PICI). With this new influx of capital, Akamis Bio is poised to accelerate its clinical development initiatives and potential launch new therapies that could significantly improve outcomes for patients battling cancer. As the company continues to innovate within the dynamic landscape of cancer treatment, it remains committed to making a meaningful impact on the lives of those affected by this formidable disease. To learn more about Akamis Bio and their groundbreaking work, visit www.akamisbio.com.
Groundbreaking Oncology Company Akamis Bio Secures $60 Million in Series A Funding
Recently funded ¡ $60.0M Series aHealthcare
Get the full Akamis Bio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
DiscreteStack
DiscreteStack is a private AI operating system that enables enterprises to deploy, govern, and scale AI on their own infrastructure â at predictable cost. Instead of relying on external models and usage-based APIs, businesses run AI on their own infrastructure - with full control over data, behavior, and cost. Designed for companies where AI moves beyond experimentation into core operations, DiscreteStack turns AI from an external dependency into an internal capability. Because when AI becomes critical, access is not enough. Ownership is.
$925.5K Seed
today
DeHaat Honest Farms
DeHaat Honest Farms is on a mission to make pesticide-free food the new standard in India, and since 2022, that mission has had a name. People are the strength behind this brand, a passionate, driven team spread across the country, united by one purpose: delivering on every promise made. Trust is at the core of everything, from the farmers we partner with to the consumers we serve.
$3.7M Pre-seed
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Groq United States | Series a | $350.0M | today |
| 2 |  Trajectory United States | Series a | $40.0M | today |
